## Management of Paraneoplastic Hypercalcemia (HHM) ### Clinical Context Humoral hypercalcemia of malignancy (HHM) accounts for ~80% of cancer-related hypercalcemia. Squamous cell lung cancer, renal cell carcinoma, and breast cancer are common culprits. PTHrP (parathyroid hormone-related peptide) mimics PTH, causing renal phosphate wasting, increased bone resorption, and enhanced intestinal calcium absorption. ### Drug of Choice: IV Normal Saline + Loop Diuretics **Key Point:** Aggressive IV hydration with isotonic saline is the cornerstone of acute hypercalcemia management. Loop diuretics (furosemide) enhance urinary calcium excretion by blocking the thick ascending limb of the loop of Henle, where calcium is normally reabsorbed. ### Mechanism of Action 1. **IV Normal Saline (0.9% NaCl)** - Expands intravascular volume and glomerular filtration rate (GFR) - Increases filtered load of calcium - Dilutes serum calcium concentration - Typical dose: 200–500 mL/hour (up to 1 L/hour in severe cases) 2. **Loop Diuretics (Furosemide)** - Block Na⁺-K⁺-2Cl⁻ cotransporter in thick ascending limb - Inhibit paracellular calcium reabsorption (normally 20–25% of filtered calcium is reabsorbed here) - Promote urinary calcium wasting - Typical dose: 40–80 mg IV every 2–4 hours **Clinical Pearl:** Thiazide diuretics are **contraindicated**—they increase distal tubular calcium reabsorption and worsen hypercalcemia. Only loop diuretics are used. ### Treatment Algorithm for Acute Hypercalcemia ```mermaid flowchart TD A[Hypercalcemia diagnosed]:::outcome --> B{Severity & symptoms?}:::decision B -->|Mild asymptomatic<br/>10-11 mg/dL| C[Hydration + observation]:::action B -->|Moderate-severe<br/>11-13 mg/dL| D[IV saline + loop diuretics]:::action B -->|Severe symptomatic<br/>≥13 mg/dL| E[Aggressive IV saline<br/>+ furosemide]:::urgent D --> F{Response in 24-48 hrs?}:::decision E --> F F -->|Inadequate| G[Add bisphosphonate<br/>or calcitonin]:::action F -->|Adequate| H[Treat underlying cancer<br/>Maintain hydration]:::action G --> I[Reassess in 3-5 days]:::action ``` ### Comparative Pharmacotherapy for Hypercalcemia | Agent | Onset | Duration | Mechanism | Use in HHM | |-------|-------|----------|-----------|------------| | **IV saline + loop diuretics** | 2–6 hours | 24–48 hours | ↑ GFR, ↑ urinary Ca²⁺ excretion | **First-line, acute** | | **Bisphosphonates** (zoledronic acid, pamidronate) | 2–3 days | 7–14 days | ↓ Osteoclast activity | Second-line, moderate-severe | | **Calcitonin** | 2–4 hours | 6–12 hours | ↓ Osteoclast activity, ↑ renal excretion | Adjunct for rapid effect | | **Denosumab** (anti-RANKL) | 3–7 days | 28+ days | Inhibits osteoclast differentiation | Refractory cases, bisphosphonate-resistant | | **Calcitriol** | Hours | Days | ↑ Intestinal Ca²⁺ absorption | **CONTRAINDICATED in HHM** | | **Vitamin D supplements** | Days | Weeks | ↑ Intestinal Ca²⁺ absorption | **CONTRAINDICATED in HHM** | **High-Yield:** Calcitriol and vitamin D are contraindicated in HHM because PTHrP already increases 1,25-dihydroxyvitamin D production. Adding more vitamin D worsens hypercalcemia. These agents are used only in granulomatous diseases (sarcoidosis, TB) where macrophages produce calcitriol. ### Monitoring During Treatment - Serum calcium, phosphate, magnesium, potassium every 6–8 hours initially - Urine output and fluid balance - Renal function (creatinine, BUN) - Symptoms (polyuria, polydipsia, confusion, cardiac arrhythmias) ### Why IV Saline + Loop Diuretics is First-Line 1. **Rapid onset** (2–6 hours) — critical in symptomatic hypercalcemia 2. **Addresses pathophysiology** — increases GFR and blocks renal calcium reabsorption 3. **Safe** — isotonic saline is physiologic; loop diuretics are well-tolerated 4. **Effective** — can reduce calcium by 2–3 mg/dL within 24–48 hours 5. **Buys time** — allows slower-acting agents (bisphosphonates, denosumab) to take effect
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.